Lates News

On August 29, Boehringer Ingelheim and China Biologic Pharmaceuticals jointly announced that their jointly promoted afatinib tablets (trade name: Saint Her Tu) in mainland China have been officially approved by the China National Medical Products Administration for the treatment of unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with HER2 (ERBB2) activating mutations who have received at least one prior systemic therapy. This is the world's first and currently only approved oral HER2 tyrosine kinase inhibitor.